Dr. Joshua Richter reviews the EXCALIBER-RRMM study evaluating iberdomide in combination with daratumumab and dexamethasone in patients with relapsed/refractory multiple myeloma.
Zachary M. Avigan, MD
Advertisement
Articles by Zachary M. Avigan, MD
Cancer Network’s FACE-OFF introduces the evolving role of cereblon E3 ligase modulators, or CELMoDs, in relapsed/refractory multiple myeloma.
The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5